TOKYO–(BUSINESS WIRE)–LUCA Science (Tokyo, Japan), a biotechnology company pioneering a novel class of mitochondrial therapeutics, announced today that it will collaborate with the University of Oxford’s Nuffield Department of Women’s & Reproductive Health, in joint research utilising LUCA Science’s proprietary drug delivery platform technology for the treatment of IUGR.
This collaboration was instigated by Dr Yosuke Matsumiya, the UK project director for LUCA Science, who will be coordinating the research with the University of Oxford.
About the Joint Research
The placenta is a unique organ across which nutrients are transferred from mother to baby. Abnormal placental function causes significant problems in pregnancy, including IUGR.
IUGR affects over 10 million babies worldwide/year with 200,000 deaths related to IUGR and survivors (often delivered prematurely) face not only the sequelae of preterm birth but also increased long-term risks of disease (metabolic & cardiac). The largest global causes of IUGR are malnutrition